An International Peer - Reviewed Journal by Nuclear Science & Technology Research Inistitute

Document Type : Research paper


1 End of kargar street, Nuclear science and Technology research Institute

2 Radioisotope Products and Radiation Technology Section, Department of Nuclear Sciences and Applications, International Atomic Energy Agency (IAEA), Vienna, Austria

3 Nuclear Fuel Cycle School, Nuclear Science and Technology Research Institute (NSTRI), 14155-1339 Tehran, Iran

4 Faculty of Nuclear Engineering and Physics, Amirkabir University of Technology, Tehran, Iran


191Os is a parent radionuclide with a 15.4 d half-life. It decays by beta emission to 191mIr, which is a radionuclidewith a 4.96s half-life. It decays by the isomeric transition to stable 191Ir, emitting a 129-keV gamma photon. In thisstudy, 191Os–phytate was developed into an in-vivo radionuclide generator for simultaneous radiosynovectomy and imaging. 191Os-hexachloroosmate was used to prepare 191Os–phytate (100 μCi/50 μl) using reaction condition optimization followed by an intraarticular injection to rat knee joints. Also, its distribution and stability were assessed. The imaging of 191Os cation and 191Os–phytate was performed by SPCET. The 191Os–phytate complex was obtained at pH=5.5 with normal saline at room temperature. Radio-TLC showed an overall radiochemical yield of 95-98%. The complex was injected into the rats’ knees, and the whole injected dose remained at the injection site even three days after injection. Due to the stability and retention of the complex in joints approved by biodistribution and imaging studies, the complex is a potential in vivo generator for cavital radiosynovectomy of minor joints.


1.  G. Clunie and M. Fischer, EANM procedure guidelines for radiosynovectomy, EJNMMI, vol. 30, pp. BP12-BP16, (2003).

2.  M. Kropacek, et al., Preparation of Holmium-166 Labelled Macroaggregates for radionuclide synovectomy, Nucl Med Rev Cent East Eur, vol. 6, pp. 1-4, (2003).

3.  Y. S. Suzuki, et al., Biodistribution and kinetics of holmium-166-chitosan complex (DW-166HC) in rats and mice, JNM, vol. 39, pp. 2161-2166, (1998).

4.  E. W. Lee, et al., Yttrium-90 selective internal radiation therapy with glass microspheres for hepatocellular carcinoma: current and updated literature review, KJR, vol. 17, p. 472, (2016).

5. I. Ikeda, et al., Evaluation of 99mTc-phytate as radiopharmaceuticalRadioisotopes, vol. 25, p. 651, (1976).

6. A. R. Jalilian, et al.,Development of 166Ho-phytate Complex for Radiosynovectomy, NMMI, vol. 45, pp. 87-92, (2011).


7.  H. Palmedo, et al., Painful Multifocal Arthritis:  Therapy with Rhenium 186 Hydroxyethylidenedi-phosphonate (186Re HEDP) after Failed Treatment with Medication—Initial Results of a Prospective Study, Radiology, vol. 221, pp. 256-260, (2001).

8. C. Cheng, et al.,  A new osmium-191 leads to iridium-191m generator, JNM: official publication, Society of Nuclear Medicine, vol. 21, p. 1169, (1980).

9.  M. Jamre, et al.,  Development  of an in vivo radionuclide generator by labeling bleomycin with 191 Os, JRNC, vol. 290, pp. 543-549, (2011).

10. C. Brihaye, et al., New osmium-191/iridium-191m radionuclide generator system using activated carbon, NMMI. (United States), vol. 3, (1986).

11. M. IAEA-TECDOC, 1340. Manual for reactor produced radioisotope, Vienna: International Atomic Energy Agency, (2003).

12. K. Kairemo, et al., 191mIr: distribution and retention in animal experiments, Nuklearmedizin, vol. 34, p. 115, (1995).